KRAS and non-small cell lung carcinoma: Detection of EGFR and KRAS mutations is now a necessary procedure for treatment of non-small-cell lung cancer (NSCLC) before using EGFR tyrosine kinase inhibitors (EGFR-TKI) [1–4].